Prostate cancer (PC) growth is driven by testosterone (T) via the androgen receptor (AR). The initial treatment of metastatic PC is (chemical) castration. Despite castrate serum T levels, patients develop castration-resistant PC (CRPC) within 1-3 years. Studies indicate that CRPC is able to synthesise its own T. It is still debated, however, whether PC tumour levels originate from de novo synthesis or via conversion of circulating adrenal steroids. Abiraterone (Abi) is a new compound that blocks the CYP17A1 enzyme required for conversion of androgen precursors into adrenal androgens, and has shown increased survival of CRPC patients post-chemotherapy.

In this study, we used parental and CRPC cell lines to test if CRPC cells use de novo steroidogenesis or conversion of adrenal androgens to support AR-stimulated growth and created an in vitro co-culture model for adrenal stimulated cell growth.

Results

CYP17A1 is a critical for androgen production

Androgen precursors induce PC growth in vitro regardless of CYP17A1 activity

Physiological levels of adrenal androgens, but not androgen precursors drive castration-naive and CRPC cell growth

Co-culture with H295R adrenal carcinoma cells can drive PC growth in castrate conditions

Future plans

To model CRPC in vivo we are planning to move forward to study tumour growth in a murine xenograft model. To replicate the hormonal environment that is normally maintained by human adrenals, H295R xenografts will be transplanted with androgens secreted by the adrenal cell line H295R induced growth in both parental and CRPC cells, which could be partially inhibited by Abi, validating previous reports that conversion of adrenal androgens is the main driver for CRPC.

Conclusion

Our results show that parental VCaP and VCaP CRPC cells do not depend on de novo steroidogenesis to survive in a testicular androgen-depleted environment. Androgens secreted by the adrenal cell line H295R induced growth in both parental and CRPC cells, which could be partially inhibited by Abi, validating previous reports that conversion of adrenal androgens is the main driver for CRPC.

Acknowledgements

The research leading to these results has received support from the Innovative Medicines Initiative (Joint Undertaking under grant agreement n° 115168; resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution. Development of CRPC clones was supported by TI-Pharma Project T3-107.

Figure 1: Overview of the steroidogenic pathway in humans. After cholesterol is converted into pregnenolone, CYP17A1 hydroxylates it to 17αOH-pregnenolone and DHEA. HSD3B enzymes can metabolize these precursors into progesterone, 17OH-progesterone and androstenedione, respectively. DHEA and androstenedione can subsequently be converted into testosterone and DHT. In humans, CYP17A1 activity is present in the testicular and adrenal glands. In mice CYP17A1 is only expressed in testicular tissue.

Figure 2: Androgen precursors induce minor growth in castration-naive and CRPC cells. Left: MTT results in VCaP parental cells. Top: pregnenolone at 100 or 10 nM induce little growth, which is inhibited at higher concentrations of Abi. Middle: progesterone is more potent at inducing growth, which is not inhibited at concentrations of Abi that adequately block CYP17-activity (0.1 µM). Bottom: DHT (10 µM) induced growth is inhibited at higher levels of Abi, suggesting a direct AR-blocking property of Abi. Right: like parental cells, VCaP DCC-E cells (cultured in steroid stripped medium and 1 µM of the anti-androgen OH-Flutamide) grow more in the presence of pregnenolone or progesterone, despite adequate CYP17A1 blockade. At higher levels of Abi, DHT-induced growth was inhibited.

Figure 3: Castration-naive and castration-resistant PC cells react similarly to levels of steroids found in the average 60 year-old male and to those found in H295R xenograft-bearing mice. In VCaP parental and VCaP-derived CRPC cell lines, no significant growth induction was observed in the presence of pregn and prog levels of adrenal androgens induced growth which could be inhibited by the novel anti-androgen MDV310, but to a lesser extent by Abiraterone. Steroid levels in nM (60 y.o. male/H295R xenograft): pregnenolone 1.5/30; progesterone 0.5/5; DHEA 10/5; androstenedione 2.5/7.5; DHT 0.1.

Figure 4: H295R adrenal cells stimulate VCaP cell growth in castrate conditions. Co-culture with adrenal cells stimulated VCaP cell growth. 1 µM Abi could partially inhibit this growth stimulus, suggesting that steroid synthesis in the adrenals, rather than de novo synthesis in PC cells is more important for AR-activation in CRPC.